Page 2 - Nasdaq Prph News Today

Garden City, NY, April 28, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next-generation biotech, genomics and diagnostics...

ProPhase Labs, Inc. (NASDAQ:PRPH – Get Rating) was the recipient of a significant growth in short interest in April. As of April 15th, there was short interest totalling 382,800 shares, a growth of 23.5% from the March 31st total of 309,900 shares. Based on an average trading volume of 45,200 shares, the days-to-cover ratio is […]

GARDEN CITY, NY, Jan. 05, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a growth oriented and diversified diagnostics,...

ProPhase Labs, Inc. (NASDAQ:PRPH – Get Rating)’s share price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $9.77 and traded as high as $10.68. ProPhase Labs shares last traded at $10.26, with a volume of 51,993 shares. Analysts Set New Price Targets A number […]

GARDEN CITY, NY, Sept. 06, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and...

GARDEN CITY, NY, Aug. 04, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and...

Investment analysts at StockNews.com began coverage on shares of ProPhase Labs (NASDAQ:PRPH – Get Rating) in a research note issued on Wednesday. The brokerage set a “strong-buy” rating on the stock. A number of other brokerages also recently issued reports on PRPH. HC Wainwright lowered their price objective on ProPhase Labs from $16.00 to $14.00 […]

ProPhase Labs (NASDAQ: PRPH) has recently received a number of price target changes and ratings updates: 6/14/2022 – ProPhase Labs is now covered by analysts at StockNews.com. They set a “sell” rating on the stock. 6/7/2022 – ProPhase Labs was upgraded by analysts at TheStreet from a “c+” rating to a “b” rating. 6/6/2022 – […]

Analysts expect that ProPhase Labs, Inc. (NASDAQ:PRPH – Get Rating) will post $18.05 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for ProPhase Labs’ earnings, with the lowest sales estimate coming in at $13.39 million and the highest estimate coming in at $22.70 million. ProPhase Labs […]

Wall Street brokerages expect ProPhase Labs, Inc. (NASDAQ:PRPH – Get Rating) to report earnings per share of $0.17 for the current quarter, according to Zacks. Two analysts have issued estimates for ProPhase Labs’ earnings, with the highest EPS estimate coming in at $0.21 and the lowest estimate coming in at $0.12. ProPhase Labs reported earnings […]